Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

July 17, 2025

PresentationTivozanib

Overview of Tivozanib (Tivo) Safety in Patients with Metastatic Renal Cell Carcinoma (mRCC)

May 30, 2025

PresentationTivozanib

Efficacy of second line (2L) treatment with Tivozanib (Tivo) as monotherapy or with Nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the Phase 3 TiNivo-2 study

February 13, 2025

PresentationTivozanib

Integrated Efficacy and Safety Exposure Response (ER) Analysis of Tivozanib (Tivo) for the Treatment of Renal Cell Carcinoma (RCC)

February 13, 2025

PresentationTivozanib

Patient-Reported Outcomes (PROs) for Tivozanib + Nivolumab (Tivo-Nivo) vs. Tivozanib (Tivo) Monotherapy in Patients With Renal Cell Carcinoma (RCC) Following an Immune Checkpoint Inhibitor (ICI): Results of the Phase 3 TiNivo-2 Study

January 6, 2025

PublicationTivozanib

Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study

Authors: Miguel Zugman, David F. McDermott, Bernard J. Escudier, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael B. Atkins, Brian Rini, Sumanta K. Pal. Click here for link to article.

October 25, 2024

PublicationTivozanib

Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients

Authors: Jeffrey Thomas Yorio, Aviva G. Asnis-Alibozek, Vijay Kasturi, Thomas E. Hutson. Click here for link to article.

1 2 3 … 12 Next »